News & Events

Redbiotec AG, a pioneer in living medicines, is pleased to announce the addition of Professor Christoph U. Schoen, MD, PhD to its Scientific Advisory Board. Dr. Schoen is a Professor of Medical Microbiology at the University of Würzburg, and the Head of the Laboratory for Diagnostic Microbiology, Institute for Hygiene and Microbiology. He is an expert in clinical microbiology, with 20 years of research experience and numerous scientific publications in the fields of patho-biotechnology, bacterial patho-genomics and diagnostic microbiology.  Dr. Schoen received his MD from Georg-August-University, and his PhD in Microbiology from Julius-Maximilians-University.

Christian Schaub, the CEO of Redbiotec, commented “We are thrilled that Professor Schoen has agreed to join our growing Scientific Advisory Board. He will be instrumental in helping our dedicated scientific team further the development of our proprietary platforms for living medicines.”

Redbiotec welcomes two new senior people: Dr. Jin Huh, a synthetic biology expert from the Massachusetts Institute of Technology (MIT) who shall provide scientific advisory to Redbiotec, and Dr. Yao Cheng joining Redbiotec as the Senior Business Development Manager. Redbiotec seeks to expand its growing scientific as well as business networks globally with these new appointments.

Redbiotec is pleased to announce the appointment of Dr. Antonio Marchini, head of Laboratory of Oncolytic-Virus-Immuno-Therapeutics (LOVIT) at the Luxembourg Institute of Health and German Cancer Research Center (DKFZ), as a member of our Scientific Advisory Board. Antonio is an expert in the field of oncolytic viruses aiming at developing innovative anticancer agents. Redbiotec looks forward to this collaboration.

Redbiotec is pleased to welcome Prof. Maries van den Broek, PhD, Professor at the University of Zurich, Institute of Experimental Immunology, as an additional exclusive member of our Scientific Advisory Board. Maries is a renowned expert in the field of tumor immunology. The aim of her work is to better understand the mutual interaction between the immune system and cancer. Redbiotec looks forward to benefiting from this collaboration.

Redbiotec recently hired three additional scientists supporting Redbiotec’s fast growing oncology program. We are happy to observe a big and growing interest in Redbiotec’s COMOS and in Redbiotec’s engineered bacteria. As a consequence Redbiotec will invest further resources in these promising immuno-oncology platforms. Redbiotec is currently also evaluating additional people strengthening its scientific advisory board.